⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
prnewswire.com
LIVN
SNAP
GE
BSX
JNJ
PFE
MRK
BMY
LLY
NVO
PHG
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
CMPX
MRK
PFE
BOLD
REPL
RDHL
RLAY
LLY
INCY
JAZZ
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
globenewswire.com
SWKS
MRK
Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence
globenewswire.com
MRK
Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence
globenewswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus WELIREG ® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
businesswire.com
MRK
WELIREG ® (belzutifan) Plus LENVIMA ® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
businesswire.com
MRK
A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall
globenewswire.com
AMGN
BMY
EXEL
EXAS
GENK
GSK
JNJ
MRK
NTRA
PFE
KEYTRUDA ® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
businesswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus Padcev ® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
businesswire.com
MRK